IRVINE, Calif., Aug. 28, 2023 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW) today announced it is scheduled to present at the 2023 Wells Fargo Healthcare Conference on Thursday, September 7, 2023.
Bernard Zovighian, chief executive officer, and Scott B. Ullem, chief financial officer, are scheduled to speak to conference attendees at 11:00 a.m. ET. A live webcast of the presentation will be available to all interested parties on the Edwards Lifesciences investor relations website at http://ir.edwards.com/. An archived version of the webcast will be available later that day on the Edwards investor relations website.
About Edwards Lifesciences
Edwards Lifesciences is the global leader of patient-focused innovations for structural heart disease and critical care monitoring. We are driven by a passion for patients, dedicated to improving and enhancing lives through partnerships with clinicians and stakeholders across the global healthcare landscape. For more information, visit Edwards.com and follow us on Facebook, Instagram, LinkedIn, Twitter and YouTube.
Edwards, Edwards Lifesciences, and the stylized E logo are trademarks of Edwards Lifesciences Corporation. All other trademarks are the property of their respective owners.
| Last Trade: | US$75.74 |
| Daily Change: | -0.98 -1.28 |
| Daily Volume: | 5,461,040 |
| Market Cap: | US$44.470B |
July 24, 2025 May 01, 2025 April 23, 2025 | |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
